# Amgen Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Amgen Inc).

## Overview

Amgen Inc. discovers, develops, manufactures and commercializes prescription biologic and small‑molecule medicines across multiple therapeutic areas, operating as a single segment (human therapeutics). The company’s business model combines in-house R&D and biologics manufacturing with global commercialization, with product demand shaped by regulatory approvals and payer reimbursement. Amgen sells primarily through pharmaceutical wholesalers in the U.S. and through a mix of wholesalers and direct-to-provider channels internationally, supported by collaborations in certain markets. Its portfolio includes established brands (e.g., Prolia, Repatha, ENBREL) alongside newer growth products and a pipeline that targets high unmet medical need.

## Products & services

• Prolia (osteoporosis)
• Repatha (LDL-C lowering; CV risk reduction label expanded)
• XGEVA (bone metastases-related indications)
• ENBREL (inflammatory diseases)
• Otezla (psoriatic disease)
• TEZSPIRE (asthma; ex-U.S. via AstraZeneca)
• Oncology/hematology brands (e.g., BLINCYTO, KYPROLIS, Vectibix)

- **General medicine (cardiometabolic, bone health, inflammation)** (55%) — Primary care and specialty medicines including bone health, lipid management and immunology/inflammation brands.
- **Oncology and hematology** (25%) — Cancer and blood-disorder therapies sold through oncology/hematology channels and hospitals.
- **Rare disease and specialty** (15%) — Specialty and rare-disease products often requiring specialist prescribing and payer authorization.
- **Other revenues (collaboration/partner and other)** (5%) — Non-product revenues such as collaboration-related income and other ancillary items.

- Prolia (osteoporosis)
- Repatha (LDL-C lowering; CV risk reduction label expanded)
- XGEVA (bone metastases-related indications)
- ENBREL (inflammatory diseases)
- Otezla (psoriatic disease)
- TEZSPIRE (asthma; ex-U.S. via AstraZeneca)
- Oncology/hematology brands (e.g., BLINCYTO, KYPROLIS, Vectibix)

## Customers

Amgen’s end customers are healthcare providers and patients, but its direct customers in the U.S. are predominantly large pharmaceutical wholesale distributors that supply pharmacies, hospitals, clinics and other care sites. McKesson, Cencora and Cardinal Health together represent the majority of worldwide gross revenues, giving these intermediaries significant purchasing leverage and making channel dynamics important to pricing and volumes. Demand and net realized price are heavily influenced by government and commercial payers, including PBMs that negotiate rebates and formulary placement and can shift share to competing therapies. Outside the U.S., Amgen sells through a mix of wholesalers and direct-to-provider channels depending on local distribution practices, and it also uses collaborations/partners in parts of Asia Pacific and for certain products (e.g., TEZSPIRE ex-U.S.).

- **U.S. pharmaceutical wholesale distributors** (primary) — Purchase large volumes for downstream distribution; central to U.S. channel access and working-capital dynamics.
- **Commercial and government payers / PBMs** (primary) — Determine coverage, reimbursement and patient access; negotiate rebates/discounts that drive net price.
- **Hospitals, clinics and physician practices** (secondary) — Prescribe and administer therapies (especially oncology and infused/injectable products) and influence product adoption.
- **International wholesalers and healthcare providers** (secondary) — Buy products under country-specific distribution models; growth depends on local access and partner execution.
- **Collaboration partners** (emerging) — Co-commercialize or commercialize in specific territories/products (e.g., TEZSPIRE ex-U.S.), affecting reach and economics.

- U.S. pharmaceutical wholesalers buy most U.S. volume for distribution
- Hospitals and health systems purchase via wholesalers for inpatient/outpatient
- Specialist clinics (oncology, rheumatology, endocrinology) drive prescribing
- Dialysis centers are important for certain nephrology-related therapies
- Retail and specialty pharmacies dispense to chronic and specialty patients
- PBMs/insurers influence access via formularies, rebates and prior auth
- Government payers (Medicare/Medicaid) affect coverage and net pricing

## Geography

Amgen markets products globally with a presence in approximately 100 countries, but product sales are concentrated in the United States. Authoritative disclosures show 2025 product sales of $25,656 million (73%) in the U.S. and $9,492 million (27%) in the rest of world (ROW), consistent with 2024 (73%/27%) and 2023 (72%/28%). Commercial operations are concentrated in the U.S. and Europe, while the company also sells in Japan, China and other parts of Asia, Latin America and the Middle East through affiliates, acquisitions of rights, and collaborations. Manufacturing footprint concentration is a key geographic exposure: a substantial majority of commercial manufacturing is in Puerto Rico and a substantial majority of clinical manufacturing is in Thousand Oaks, California.

- **United States** (73%) — 2025 product sales by geography (10-K 2025 excerpt)
- **Rest of World** (27%) — 2025 product sales by geography (10-K 2025 excerpt)

- U.S. is 73% of 2025 product sales; payer policy drives net pricing
- ROW is 27% of 2025 product sales; FX and access vary by country
- Sales/marketing concentration in U.S. and Europe supports key launches
- Asia Pacific presence often uses partners (e.g., Astellas, Takeda)
- Commercial manufacturing concentrated in Puerto Rico (single-site risk)
- Clinical manufacturing concentrated in Thousand Oaks, California
- Tariffs/trade measures can affect supply chain and sourcing choices

## Strategy

Amgen’s strategy centers on investing in innovation (internal R&D and external business development) while scaling manufacturing capacity to support both marketed products and pipeline assets. The company allocates capital across R&D, capacity expansion, debt repayment, dividends and share repurchases, reflecting a balance between growth investment and shareholder returns. Commercially, it seeks to expand indications and labels for existing brands (e.g., Repatha’s broadened FDA-approved use) to widen eligible patient populations and improve access. Internationally, Amgen uses a mix of direct affiliates and collaborations to reach markets where local scale, regulatory pathways or distribution practices favor partnering.

- **Scale manufacturing capacity and resilience** (medium-term) — Biologics supply reliability underpins revenue and launch execution; site concentration heightens the need for resilience.
- **Drive growth from existing brands via lifecycle management** (short-term) — Label expansions and new indications can extend product life and increase volume without full new-product risk.
- **Portfolio expansion through internal and external innovation** (long-term) — Biopharma revenue durability depends on replenishing products facing competition and pricing pressure.

- Invest in pipeline and external innovation to refresh the portfolio
- Expand manufacturing capacity via multi-year capital projects
- Pursue label expansions to increase addressable patient populations
- Use collaborations to commercialize efficiently in select markets
- Optimize capital structure via debt repayment, dividends and buybacks
- Actively manage supply chain to mitigate tariffs and trade friction

## Risks

Amgen’s revenue is exposed to payer coverage and reimbursement decisions, with pricing pressure amplified by consolidation among PBMs and wholesalers that can demand higher rebates/discounts or shift volume to competitors. The company faces development and regulatory risk because product candidates and new indications require clinical trials and regulatory approvals, and some products rely on companion diagnostics or delivery devices with their own compliance risks. Operationally, manufacturing concentration in Puerto Rico (commercial) and Thousand Oaks (clinical) creates single-site disruption risk, compounded by reliance on certain sole-source third-party suppliers for raw materials and components. International operations add exposure to tariffs, trade measures, foreign exchange and geopolitical disruptions, while cybersecurity incidents at third-party service providers can create data, operational and compliance risks.

- **Coverage, reimbursement and pricing pressure from payers/PBMs** [high] — Government and commercial payers influence access and net price; PBM consolidation increases negotiating leverage and risk of exclusion.
- **Customer concentration in three U.S. wholesalers** [high] — McKesson, Cencora and Cardinal Health each exceed 10% of revenues; combined ~77% of worldwide gross revenues, increasing bargaining power and credit exposure.
- **Manufacturing disruption at key sites** [critical] — A substantial majority of commercial manufacturing is in Puerto Rico and clinical manufacturing in Thousand Oaks; disruptions could impair supply and trials.
- **Third-party supplier dependency (including sole-source inputs)** [high] — Certain raw materials, devices and components are proprietary to unaffiliated suppliers; shortages/quality issues can constrain production.
- **Cybersecurity incidents at third-party service providers** [medium] — Supplier breaches have occurred with unauthorized access/exfiltration; delayed or incomplete incident reporting can impair response and increase impact.

- Wholesaler concentration (top 3 ~77% of gross revenues) pressures pricing
- PBM consolidation increases rebate demands and formulary exclusion risk
- Regulatory approval and clinical trial failure can delay/stop launches
- Manufacturing concentration in Puerto Rico/Thousand Oaks raises outage risk
- Sole-source suppliers for materials/devices can constrain supply
- Tariffs/trade protection measures can increase costs and disrupt sourcing
- Third-party cybersecurity incidents can expose data and disrupt operations
- Climate change/natural disasters can disrupt facilities and logistics

## Accounting

Amgen recognizes product sales revenue when control transfers to the customer (generally upon delivery) and reports revenue net of significant sales deductions such as rebates, chargebacks and discounts, making estimation of these accruals a key driver of net sales and period-to-period comparability. Management reassesses sales-deduction accrual adequacy quarterly, and true-ups to actual experience can shift revenue between periods, particularly given the role of PBMs and government programs in rebate mechanics. The company’s financial statements can be affected by impairment judgments for acquired intangibles and other long-lived assets, as illustrated by an Otezla intangible asset impairment charge referenced in interim reporting. Given global operations and collaborations, investors also monitor how foreign currency movements and partner-related revenues affect reported results and disclosures, even when underlying demand is stable.

- **Product sales deductions (rebates, chargebacks, discounts)** — Net product sales, accrued liabilities, period-to-period volatility
- **Intangible asset impairment** — Operating income and asset carrying values

- Revenue recognized on delivery; net of rebates, chargebacks, discounts
- Quarterly true-ups of sales-deduction accruals can move net sales
- Estimates tied to payer mix and rebate programs affect gross-to-net
- Impairment testing for intangibles can create large one-time charges
- Acquisition accounting can affect inventory step-up amortization timing
- FX can affect international revenue translation and comparability

---

*Last updated: 2026-08-11T04:03:56.228997+00:00*